References
- Souen S. Mortality and causes of death in RA patients. Rheu-matology. 2007;37:164–8.
- Shinomiya F, Mima N, Nanba K, Tani K, Nakano S, Egawa H, et al. Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period. Mod Rheu-matol. 2008;18:165–9.
- Takasaki Y. Steroids. In: Ochi T, Yamamoto K, Ryu J, editors, Therapeutic manual for rheumatoid arthritis (revised edition), diagnostic manual and EBM guidelines for treatment. Tokyo: Japan Rheumatism Foundation; 2004. p. 78–83.
- McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet. 2004;363:2015–21.
- Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, et al. Activation of human aortic smooth-muscle cells is inhibited by PPAR alpha but not by PPAR gamma activators. Nature. 1998;393:790–3.
- Council for Evaluation of the Diagnostic Criteria for Metabolic Syndrome: definition of metabolic syndrome and diagnostic cri-teria. J Jpn Soc Intern Med. 2005;94:794–809.
- Hakoda M, Oiwa H, Kasagi F, Masunari N, Yamada M, Suzuki G, et al. Mortality of rheumatoid arthritis in Japan: a longitudinal cohort study. Ann Rheum Dis. 2005;64:1451–5.
- Kanda H, Hamasaki K, Kubo K, Tateishi S, Yonezumi A, Kanda Y, et al. Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis. J Rheumatol. 2002;29:2024–6.
- Okamoto H, Kamatani N. Successful treatment with fenofibrate, a peroxisome proliferator activated receptor alpha ligand, for a patient with rheumatoid arthritis. Ann Rheum Dis. 2004;63: 1002–3.
- Murai T, Arai K, Fujisawa J, Kondo N, Endo N, Hanyu T, et al. Evaluation of usefulness of fenofibrate in treatment of rheumatoid arthritis. In: General meeting of Japan College of Rheumatology, Academic Meeting, International Rheumatology Symposium Program. Proceedings (50th/15th), 2006 April 23–26; Nagasaki, Japan. 2006, p. 280.
- Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IKBa expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem. 2000;275:36703–7.
- Okamoto H, Iwamoto T, Kotake S, Momohara S, Yamanaka H, Kamatani N. Inhibition of NF-KB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheu-matol. 2005;23:323–30.
- Lazzerini PE, Lorenzini S, Selvi E, Capecchi PL, Chindamo D, Bisogno S, et al. Simvastatin inhibits cytokine production and nuclear factor-KB activation in interleukin 1/3-stimulated syno-viocytes from rheumatoid arthritis patients. Clin Exp Rheumatol. 2007;25:696–700.
- Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.
- Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–61.
- Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syn-drome. Diabetes Care. 2007;30:1945–51.
- Goto M. Inflammaging (inflammation ± aging): a driving force for human aging based on an evolutionarily antagonistic pleiot-ropy theory? BioScience Trends. 2008;2:218-30.